Five Potential Blockbuster Oncology Approvals To Look Out For In 2023

 
• By Ayisha Sharma

With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.    

Piggy Money
These Pipeline Drugs Could Exceed $1bn In Sales • Source: Shutterstock

More from Anticancer

More from Therapy Areas